Tempest Therapeutics (TPST) Operating Margin (2015 - 2018)
Tempest Therapeutics' (TPST) quarterly Operating Margin came in at 14192.73% in Q3 2018, up 260370.0% year-over-year from N/an in Q3 2017, and down 130.57% quarter-over-quarter from 6155.56% in Q2 2018.
Powered by 
Analysis
Tempest Therapeutics (TPST) Operating Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has disclosed Operating Margin across 4 years of filings, most recently posting 14192.73% for Q3 2018.
- In Q3 2018, Operating Margin rose 260370.0% year-over-year to 14192.73%; the TTM figure through Sep 2018 stood at 20266.67% (down 42377.0% YoY), while the FY2017 annual figure was 28585.08%, down 1617896.0% from the prior year.
- Operating Margin came in at 14192.73% for Q3 2018 at Tempest Therapeutics, down from 6155.56% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 6155.56% in Q2 2018 to a low of 112086.67% in Q1 2015.
- Average Operating Margin over 4 years is 26210.66%, with a median of 16796.43% recorded in 2017.
- Year-over-year, Operating Margin surged 9740242 bps in 2016 and sank 2811185 bps in 2017.
- Over 4 years, Operating Margin stood at 12891.72% in 2015, then plunged by 43 bps to 18485.95% in 2016, then sank by 152 bps to 46597.8% in 2017, then jumped by 70 bps to 14192.73% in 2018.
- Per Business Quant data, the three most recent Operating Margin figures were 14192.73% in Q3 2018, 6155.56% in Q2 2018, and 6549.25% in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -25,827.14% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.56% |
| 10 | Tempest Therapeutics | 3.35 Mn | 2.55 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | -14,192.73% |
| Jun 30, 2018 | -6,155.56% |
| Mar 31, 2018 | -6,549.25% |
| Dec 31, 2017 | -46,597.80% |
| Sep 30, 2017 | -16,796.43% |
| Jun 30, 2017 | -21,345.24% |
| Mar 31, 2017 | -23,153.97% |
| Dec 31, 2016 | -18,485.95% |
| Sep 30, 2016 | -9,626.40% |
| Jun 30, 2016 | -9,651.32% |
| Mar 31, 2016 | -14,684.25% |
| Dec 31, 2015 | -12,891.72% |
| Sep 30, 2015 | -23,696.00% |
| Jun 30, 2015 | -57,246.67% |
| Mar 31, 2015 | -112,086.67% |